Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 3.79
(-0.94%)
USD 3.79
(-0.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -39.15 Million USD | 51.87% |
| 2022 | -81.35 Million USD | 25.66% |
| 2021 | -109.43 Million USD | -13.72% |
| 2020 | -96.23 Million USD | -9.08% |
| 2019 | -88.22 Million USD | -36.31% |
| 2018 | -64.72 Million USD | -62.31% |
| 2017 | -39.87 Million USD | -22.06% |
| 2016 | -32.66 Million USD | -104.87% |
| 2015 | -15.94 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -11.77 Million USD | -26.04% |
| 2024 Q2 | -9.63 Million USD | 18.42% |
| 2023 Q1 | -11.68 Million USD | -13.97% |
| 2023 Q3 | -8.76 Million USD | 8.72% |
| 2023 Q2 | -9.59 Million USD | 17.84% |
| 2023 FY | -39.15 Million USD | 51.87% |
| 2023 Q4 | -9.34 Million USD | -6.61% |
| 2022 FY | -81.35 Million USD | 25.66% |
| 2022 Q4 | -10.25 Million USD | 29.64% |
| 2022 Q3 | -14.56 Million USD | 45.68% |
| 2022 Q2 | -26.82 Million USD | 13.07% |
| 2022 Q1 | -30.85 Million USD | 34.1% |
| 2021 Q1 | -28.31 Million USD | 2.31% |
| 2021 Q3 | -26.07 Million USD | 10.24% |
| 2021 Q4 | -46.81 Million USD | -79.57% |
| 2021 Q2 | -29.04 Million USD | -2.58% |
| 2021 FY | -109.43 Million USD | -13.72% |
| 2020 Q2 | -21.28 Million USD | -5.74% |
| 2020 Q4 | -28.98 Million USD | -12.16% |
| 2020 Q1 | -20.12 Million USD | 0.36% |
| 2020 FY | -96.23 Million USD | -9.08% |
| 2020 Q3 | -25.84 Million USD | -21.44% |
| 2019 Q1 | -24.05 Million USD | -2.05% |
| 2019 FY | -88.22 Million USD | -36.31% |
| 2019 Q4 | -20.19 Million USD | 6.35% |
| 2019 Q3 | -21.56 Million USD | 3.76% |
| 2019 Q2 | -22.41 Million USD | 6.82% |
| 2018 Q2 | -14.51 Million USD | -30.34% |
| 2018 Q1 | -11.13 Million USD | 0.01% |
| 2018 Q3 | -15.49 Million USD | -6.73% |
| 2018 Q4 | -23.56 Million USD | -52.09% |
| 2018 FY | -64.72 Million USD | -62.31% |
| 2017 Q1 | -9.57 Million USD | -16.78% |
| 2017 Q2 | -9.63 Million USD | -0.62% |
| 2017 FY | -39.87 Million USD | -22.06% |
| 2017 Q4 | -11.14 Million USD | -16.84% |
| 2017 Q3 | -9.53 Million USD | 1.0% |
| 2016 Q4 | -8.19 Million USD | 15.91% |
| 2016 Q2 | -9.65 Million USD | -90.11% |
| 2016 Q1 | -5.07 Million USD | 0.0% |
| 2016 Q3 | -9.74 Million USD | -1.01% |
| 2016 FY | -32.66 Million USD | -104.87% |
| 2015 FY | -15.94 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 76.857% |
| Dynavax Technologies Corporation | -37.02 Million USD | -5.739% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 67.774% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.722% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -643.082% |
| Perrigo Company plc | 151.9 Million USD | 125.776% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 85.814% |
| Illumina, Inc. | -1.06 Billion USD | 96.337% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.571% |
| Nektar Therapeutics | -137.42 Million USD | 71.51% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 91.499% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 101.98% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 64.604% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 12.345% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 120.136% |
| Waters Corporation | 817.67 Million USD | 104.788% |
| Biogen Inc. | 1.29 Billion USD | 103.019% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 85.711% |
| Adicet Bio, Inc. | -152.03 Million USD | 74.248% |
| Evolus, Inc. | -49.23 Million USD | 20.474% |
| bluebird bio, Inc. | -244.26 Million USD | 83.971% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 59.784% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 74.831% |
| FibroGen, Inc. | -281.81 Million USD | 86.107% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 102.9% |
| Homology Medicines, Inc. | -48.25 Million USD | 18.862% |
| Geron Corporation | -193.94 Million USD | 79.812% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 86.125% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 13.143% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 46.726% |
| Myriad Genetics, Inc. | -123.7 Million USD | 68.348% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.967% |
| OPKO Health, Inc. | -157.02 Million USD | 75.065% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 61.168% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 92.402% |
| Zoetis Inc. | 3.06 Billion USD | 101.276% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 18.77% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 103.601% |
| Exelixis, Inc. | 170.88 Million USD | 122.912% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.909% |
| uniQure N.V. | -282.87 Million USD | 86.159% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 29.778% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 83.111% |
| Verastem, Inc. | -92.08 Million USD | 57.481% |
| Imunon, Inc. | -21.03 Million USD | -86.173% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 88.931% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 85.381% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 115.605% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 136.495% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 111.598% |
| TG Therapeutics, Inc. | 20.63 Million USD | 289.759% |
| Blueprint Medicines Corporation | -486.27 Million USD | 91.948% |
| Insmed Incorporated | -709.62 Million USD | 94.483% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 89.999% |
| Incyte Corporation | 620.52 Million USD | 106.31% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 94.61% |